| P50 | author | Robert Motzer | Q42721742 |
| | Frede Donskov | Q43282917 |
| | Cora Sternberg | Q50385202 |
| | Toni K Choueiri | Q88414622 |
| P2093 | author name string | Thomas E Hutson | |
| | David F McDermott | |
| | Neeraj Agarwal | |
| | Bruce J Roth | |
| | Brian I Rini | |
| | Bernard Escudier | |
| | Daniel Y C Heng | |
| | Manuela Schmidinger | |
| | Christian Scheffold | |
| | Thomas Powles | |
| | Sumanta Pal | |
| | Nizar M Tannir | |
| | Colin Hessel | |
| | Hans J Hammers | |
| | Jae Lyun Lee | |
| | Katriina Peltola | |
| | Paul N Mainwaring | |
| | Dana T Aftab | |
| | Gisela Schwab | |
| | METEOR investigators | |
| P2860 | cites work | New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) | Q28131668 |
| | Sunitinib versus interferon alfa in metastatic renal-cell carcinoma | Q28282757 |
| | Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial | Q29615711 |
| | Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial | Q29618031 |
| | Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy | Q34007924 |
| | Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET. | Q34217927 |
| | Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma | Q34293726 |
| | Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma | Q34495684 |
| | Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. | Q34633525 |
| | Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models | Q34978329 |
| | Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer | Q35010777 |
| | EAU guidelines on renal cell carcinoma: 2014 update. | Q35548292 |
| | The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study | Q35561464 |
| | c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma | Q36551653 |
| | Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors | Q37765246 |
| | Targeted therapies for renal cell carcinoma: review of adverse event management strategies | Q37974894 |
| | Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. | Q38062681 |
| | Targeting the hepatocyte growth factor/c-Met signaling pathway in renal cell carcinoma | Q38122564 |
| | A phase I study of cabozantinib (XL184) in patients with renal cell cancer. | Q38430335 |
| | Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth | Q39472261 |
| | Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma | Q41316099 |
| | Kidney cancer, version 3.2015. | Q41407499 |
| | Preclinical evaluation of imaging biomarkers for prostate cancer bone metastasis and response to cabozantinib. | Q42231093 |
| | Differential expression of Axl and Gas6 in renal cell carcinoma reflecting tumor advancement and survival. | Q45945576 |
| | Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. | Q46006772 |
| | Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial | Q59571527 |
| | Updated EAU Guidelines for Clear Cell Renal Cancer Patients Who Fail VEGF Targeted Therapy | Q86570241 |
| P433 | issue | 7 | |
| P921 | main subject | renal cell carcinoma | Q1164529 |
| | phase III clinical trial | Q42824827 |
| P304 | page(s) | 917-927 | |
| P577 | publication date | 2016-06-05 | |
| P1433 | published in | Lancet Oncology Commission | Q13747613 |
| P1476 | title | Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial | |
| P478 | volume | 17 | |